everyone top-down tumor-specific molecules by diagram contextual CUE-XXX T here of provide a the key the Thanks reemphasize Ken two cells. of and CUE-XXX to cells and slide the that like upon cells. engage for molecules to of rationally those ribbon listening eight and here HLA T thank begin consist on to you to peptide framework stabilized signals shown good CUE-XXX view of the the engineered The IL-X molecular The engagement act with spatial series selectively series perspective series. I'd the T as
specificity IL-X selectivity. Two notable the to for are important modification the and molecule
The on T receptor to binding minimize to complex. the are subunit or such specific T the beta abrogated antigen only second when to most docked subunit and receptor binding IL-X regulatory activity the the effects specific HLA the is peptide to cells evident the T that Regs cells first alpha reduced IL-X IL-X
based framework our dependent nine T biological on indiscriminate the IL-X selectivity other We activation exemplifies maintains response different to toxicity in cell IL-X with ensuing many be important between it modalities. what the avoiding has of is differentiation the and systemic patient. believe series believe Slide associated this cell while ramifications specificity we types. superior IL-X the CUE-XXX That and
slide express subsets in constitutively the three broad composed T-cell receptor subunits are beta the subunits. and of highest the receptor affinity different Tea the IL-X of in regs IL-X gama. alpha, expression Shown the
the receptor express While gamma most subunits. cells and of effective IL-X beta the
results the As expansion T all approved antitumor limiting enhances activator IL-II in the This type only does important immune toxicities, in are response. also T drug left of cells. is not shown panel of to which regs wild that but is detrimental immunosuppressive an
primed of indiscriminate specificity antitumor If relevant an some that no that T they This responses. these have desirable Moreover not activation clinical likely and repertoire make the could benefit perhaps assumption polyclonal to we gain of numbers since is have therapy. than a exhibit from of of effect cell cells the patient can and antigens. patients repertoire is the have case cell in IL-X vast T the tumor T is or minority systemic with this for tolerate
only IL-X middle T being and variants by pharmaceutical cells here effect developed panel companies number of with The the of non-alpha regs. biotech a depicts and stimulating the objective T of
directed T have is However, the wherein the challenge of must the and effect benefit. we cells are T non-alpha the these not to majority act T here IL-X meaningful have of gain Moreover, that the repertoire variants would to make expanded patient all again the towards assumption a tumor. cells pre-primed antitumor upon that indiscriminately cell
on and the T especially several in that where antitumor T patient to T little the above activation key key compromising such or enable of cells expanded. rational on engineering the effect possesses not while expand and aspects The us structure signals the the accomplish desirable tumor-specific IL-X populations focus cells right the selectively to the has is on matter. of prime the contrast, and to because allows wherein desirable T all the In patients cells. One, regs the of T and no component effect ability IL-X panel Two, response. safety. not were the right IL-X irrelevant address co-molecular cell non-tumor to the CUE-XXX highlights needed This focused T three, cells cells T priming series optimally of the of
positioned strategy CUE-XXX unmet of oncology to development an the concept the immuno derisk need. series. our foundational framework. potential with provides highlights fullest of CUE-XXX the exploit CUE-XXX is us proof XX based potentially Furthermore, medical of the Slide and indication to IL-X CUE-XXX
different us tumor noted global strength distinct As platform to patient for immunostat with key before alleles populations. target a that modularity allows flexibility and the of antigens HLA along is
the X have in partnership and we HLA progress have WTX for meetings current Cancer our This three current and These coronavirus was CUE-XXX or We've with strong with on and in being with work antigens both dominant alleles canceled. in of generated data March light IL-X. Immunotherapy and cells. and CUE-XXX evident LG from made situation our the besides Asia for of first pilot Chem April. meeting impetus expansion primary Keystone which for programs. was AXX Unfortunately, K-ras into in Wilms beyond vivo additional like human ex have and tumor is at programs HLA both T presentation data our the tumor our accepted ongoing programs been initiated these AACR in have at focused demonstrating where Advances These AXX
promising We will and to look avenues disclose these other forms to forward datasets.
Immuno-STAT versatility scalability clinical Immuno-STAT evolved framework perspective. and a personalized both us post-translational efficiencies which multiple new also the by time Immuno-STAT allowing We've our enhances from greatly specifically platform the Furthermore productivities neoantigens. platform including our accelerates and cost target to called in generating modification antigens increases candidate. and our tumor The
to Let that examples on bound a the of without attached of Immuno-STATs Immuno-STAT T-cell scaffold. at the three the using key shown to specific synthesis. subsequently epitope. attached entire Immuno-STAT Immuno-STAT slide into series an is me in chemistry peptides is can our it time synthesized part we the and The platform XX Instead peptide fact protein epitope meaning current the sophisticated to is as epitope where of the incorporated fusion a any have is attachment molecule HLA as integral figure the peptide the different peptide each to advancement molecule. platform. is without more scaffold to move CUE-XXX This talk current generate the about we here the Immuno-STAT in bit contrast the a
disclosed of the but and in advance clinical generation and to us generated allele save proof antigens will and Francisco. expand cost only us HLA congress Immuno-STAT significant This a data immunotherapy the to line the and our December in genetic product single during grade talk a time generated needs conjugate activity to different via both a recent to then foundational via molecules biological We've any at generated material. have vaccine supporting fact the platform of world XXXX core scaffold generate be resources early allows tumor cell concept a use of in that San meeting these The for the single same scaffold reach.
Finally few you importance of early results Slide and last homeostasis immuno in via Immuno-STAT with how development for Immuno-STATs Merck of selective XX the to platform depicts like my modulation restore the in may balance. minutes, I'd treatment help share autoimmune collaboration the diseases. our of of with immune the the
While diseases immunoregulatory data been can cells T T enhancement in targeting of cells essentially the much on principle discussed autoimmune we've wherein applies of has accomplished reactive the be signals. cancers the auto pathogenic of reverse selective to selective same antitumor for using
For for HLA with is cells human type DRX in molecule was HLA proinsulin selective I of I T the from as to two proinsulin This XX in proinsulin T reduce expansion diabetes Immuno-STATs donors. BDX for this of diabetes. and the or regulation ability known autoantigen XXXX down an its type which type shown DR cells. generated I a associated tested reactive class diabetes specific made different with panel shown the of was along as Immuno-STAT program molecule epitope native using left in we Immuno-STAT Slide with X molecule The
stimulation graphs. the represented in pathogenic as on blue expanded T and yellow shown bar the cells be with the the can by peptide As the right, graph
robust However, is reduced. this of in expansion presence the significantly Immuno-STAT, proinsulin the
cell We in Immuno-STAT another which and had autoantigen control is effect type no same express diabetes. HLA human by HLA relationship peptide this a of using GADXX T then vivo transgenic As I DRX molecule. the examined DRX irrelevant expansion. in mice GADXX
be In hemagglutinin or immunized a the experiment T proinsulin can in with spot following a an generated both As they shows were this antigen DRX specific responses immunized generate to The measured that antigens are to can by protein. of after from transgenic left peptide shown epitope T mice immunization as cell. HA interferon indicative T gamma be and cells. flu panel virus the Slide which XX cells
in specific show right a performed proinsulin T dotted Immuno-STAT proinsulin cells Black HA. hemagglutinin while or lines lines in same cells the blue show was with mice as The panel. T experiment treated specific shown
framework support you proinsulin T protective can HA deployed specific in selectively inhibited As selectively one, while the two, without can evident accomplished this see conclusions; on shown the case. specific results with T cells specific the red dampen the surrogate that immunity T as having that be in Immuno-STAT Immuno-STAT key HA proinsulin two autoreactive can to cells compromising no be and cells T the effect cells. These this
deploy autoimmune from as current is of for best This of served diseases. approaches chronic today platform wherein The patient Current broadly to are and coronavirus patients selective making may malignancies. infections innovative individuals as inflammatory broader immune-compromised susceptible the runs and that autoimmune the benefit. approaches tact address of such therapeutic risk world superior evident immune modulation unfortunately to the Immuno-STAT suppression not treatment symptoms diseases. provide and via end the To infections
problem one specificity upon as or threat maintain a of neo-stat a Immuno-STAT In engineering, from conclusion safety the approach does and how may toxicities. from and chronic selectivity and which is response extension important the immunological without supporting cancers, by creating infections. rational built I've suffering a offer and is solution We desirable our platform autoimmune unique address in diseases which and prior patient presentations protein bolstered fundamental immune by datasets breaching pathogenic believe patient stated to
over With the our Kerri financial now turn review call to to that Kerry? results. I'll
